ViiV, Vertex Sue Over Mylan's Bid To Market Generic Lexiva

Law360, New York (August 24, 2012, 1:13 PM EDT) -- ViiV Healthcare Co. and Vertex Pharmaceuticals Inc. slapped Mylan Inc. with a patent infringement lawsuit in Delaware on Wednesday over Mylan's bid for U.S. regulatory approval to make and sell a generic version of the anti-HIV drug Lexiva.

North Carolina-based ViiV and Massachusetts-based Vertex said that Mylan infringed a patent owned by Vertex, and exclusively licensed to ViiV, when it submitted an abbreviated new drug application to the U.S. Food and Drug Administration seeking a green light for the manufacture, use and sale of generic fosamprenavir...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.